Compare TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $213.44 (market cap $39.15B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 3.9× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock for 111 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| TTWO | XBI | |
|---|---|---|
Market Cap | $39.15B | $10.11B |
Volume | 2,708,429 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $262.29 | $169.55 |
52-Week Low | $189.69 | $104.99 |
Typical Hold Time | 111 Days | 38 Days |
Enterprise Value | $40.27B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Take-Two Interactive (TTWO) trades at $209.37, up 2.63% today, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating in Q4 2025 and Q1 2026 but missing in Q2 2026, while the company reaffirmed the GTA VI launch date for November 19, 2026. Financials reveal negative net income margins and elevated debt levels, though revenue growth is projected to $6.7B in 2026. The stock is near its pivot point of $209, with support at $206 and resistance at $212.
The outlook hinges on GTA VI's successful launch driving revenue growth and profitability improvements. Risks include execution challenges, competitive pressures, and high valuation multiples. Analyst optimism, with a $292.30 price target, suggests significant upside if operational targets are met, but investors must weigh near-term losses against long-term game release catalysts.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
